share_log

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

SEC announcement ·  Mar 18 11:00
Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger DKK 20 billion buyback plan set to occur over a 12-month period. As of March 18, 2024, Novo Nordisk has repurchased 1,230,000 B shares at an average price of DKK 855.73 per share, amounting to a total expenditure of DKK 1,052,551,945. These transactions have increased the company's treasury shares to 47,770,707 B shares, which represents 1.1% of the share capital. The total number of A and B shares in the company, including treasury shares, is 4,510,000,000. Novo Nordisk's share repurchase initiative is part of its commitment to driving change in the treatment of serious chronic diseases, leveraging its heritage in diabetes care. The company, founded in 1923 and headquartered in Denmark, employs approximately 63,400 people across 80 countries and markets its products in roughly 170 countries.
Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger DKK 20 billion buyback plan set to occur over a 12-month period. As of March 18, 2024, Novo Nordisk has repurchased 1,230,000 B shares at an average price of DKK 855.73 per share, amounting to a total expenditure of DKK 1,052,551,945. These transactions have increased the company's treasury shares to 47,770,707 B shares, which represents 1.1% of the share capital. The total number of A and B shares in the company, including treasury shares, is 4,510,000,000. Novo Nordisk's share repurchase initiative is part of its commitment to driving change in the treatment of serious chronic diseases, leveraging its heritage in diabetes care. The company, founded in 1923 and headquartered in Denmark, employs approximately 63,400 people across 80 countries and markets its products in roughly 170 countries.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more